Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma

Authors

Stephen M Ansell, University of Manchester
Nancy L Bartlett, Washington University School of Medicine in St. Louis
et al.

Journal

New England Journal of Medicine

Publication Date

7-28-2022

Volume

387

Issue

4

First Page

310

Last Page

320

Document Type

Open Access Publication

DOI

10.1056/NEJMoa2206125

Rights and Permissions

Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125 Copyright © 2022 Massachusetts Medical Society. Reprinted with permission.

Recommended Citation

Ansell, Stephen M; Bartlett, Nancy L; and et al., "Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma." New England Journal of Medicine. 387, 4. 310 - 320. (2022).
https://digitalcommons.wustl.edu/oa_4/1036

Additional Links

Supplemental material is available for this article at publisher site.